Mission Statement, Vision, & Core Values (2026) of Sunflower Pharmaceutical Group Co.,Ltd.

Rooted in a commitment to high-quality pharmaceuticals and driven by a mission to innovate, collaborate, and ensure accessibility, Sunflower Pharmaceutical Group Co., Ltd. - founded in 2005 and headquartered in Harbin - develops traditional Chinese, chemical and biological medicines across tablets, capsules, granules, syrups, ointments and sprays to serve pediatrics, gynecology, digestive, respiratory, rheumatic bone and cardiovascular needs; the company's brand earned recognition as a China Famous Trademark in 2007, it reached markets in 20+ countries with approximately 60% of sales concentrated in Asia, and its vision to build a billion-scale 'Sunflower Carrier Battle Group' by its 20th anniversary in 2018 underscores an ambition for industrial scale, international competitiveness and a values-driven focus on innovation, integrity, cooperation, inclusiveness and responsibility

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) - Intro

• Founded: 2005 - Headquarters: Harbin, Heilongjiang Province, China
• Brand recognition: "Sunflower" trademark - China Famous Trademark (2007)
• Global reach: operations in 20+ countries - primary market Asia (~60% of sales)
• Product portfolio: tablets, capsules, granules, syrups, ointments, sprays
• Therapeutic focus: pediatrics, gynecology, digestive system, respiratory, rheumatic bone disease, cardiovascular and cerebrovascular

Mission

• Deliver safe, effective and affordable medicines that integrate TCM and modern pharmaceuticals to improve patient outcomes across primary care and specialty settings.
• Support healthcare accessibility by expanding distribution to underserved regions and partnering with local health initiatives.

Vision

• Be a leading, integrated Chinese pharmaceutical group recognized domestically and in Asia for innovation in TCM, chemical and biological therapeutics.
• Create sustainable value for patients, healthcare partners and shareholders through responsible growth, quality manufacturing and international expansion.

Core Values

• Patient-centricity: prioritize safety, efficacy and accessibility in every product decision.
• Integrity: adhere to rigorous quality, regulatory and ethical standards across R&D, production and commercialization.
• Innovation: blend traditional Chinese medical knowledge with modern biotech and chemical R&D to develop differentiated therapies.
• Collaboration: build partnerships with hospitals, research institutes, NGOs and distributors to scale impact.
• Social responsibility: invest in community health programs, disaster relief and affordable care initiatives.

Strategic Priorities & Execution

• R&D integration - expand pipelines that combine TCM compounds with standardized chemical and biological platforms to target high-burden indications in pediatrics and chronic disease.
• Manufacturing capacity - modernize GMP-compliant facilities to increase production flexibility across tablets, granules and biologics.
• Market expansion - strengthen Asian distribution (current ~60% share) while scaling exports to emerging markets in Africa and Latin America.
• Quality & compliance - maintain regulatory approvals and invest in pharmacovigilance to protect brand reputation and market access.
• CSR scaling - extend community clinics, health education and NGO partnerships to increase measurable patient reach (hundreds of thousands served via programs to date).

Operational & Financial Context

• Revenue mix: domestic markets + hospital/retail channels + export markets; Asia accounts for the largest share (~60%).
• Cost structure: material inputs for TCM and APIs, manufacturing fixed costs for multi-form production lines, R&D investment aimed at combination-TCM/modern drug development.
• Capital allocation: reinvestment into GMP upgrades, R&D pipeline funding and selective M&A to access biologics capabilities and regional distribution networks.

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) Overview

• Mission Statement: Provide high-quality pharmaceutical products that meet evolving needs of healthcare professionals and patients.
• R&D Focus: Continuous investment in drug discovery, formulation improvements, and clinical development to expand therapeutic options.
• Quality Commitment: Maintain GMP-compliant manufacturing processes and stringent quality assurance across production lines.
• Accessibility & Affordability: Pricing strategies and distribution initiatives designed to maximize patient access across regions.
• Collaboration: Partnerships with hospitals, research institutes, and distribution networks to improve treatment outcomes.

• Increase R&D intensity to expand pipeline: target 7-8% of revenue over 3 years.
• Scale manufacturing capacity while maintaining >99% batch release quality rate.
• Reduce patient cost burden via pricing programs and broader reimbursement coverage.
• Deepen clinical collaborations to accelerate real-world evidence generation and optimize product labels.

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) - Mission Statement

• Mission core: develop and deliver accessible, high-quality therapeutic products that improve patient outcomes globally.
• Strategic pillars: integration of industry chains, capitalization, product portfolio breadth, R&D-led high-end technology, and global market expansion.
• Social commitment: contribute to healthcare accessibility and sustainable industry growth while maintaining ethical standards and regulatory compliance.

• Becoming a globally competitive biopharmaceutical and healthcare group with international trust and recognition.
• Establishing a billion-scale 'Sunflower Carrier Battle Group' in the pharmaceutical industry-a stated target tied to its 20th anniversary in 2018.
• Scaling product serialization and industrial matching to serve diversified therapeutic areas and international markets.
• Prioritizing innovation, integrity, cooperation, inclusiveness, and responsibility as guiding values for sustainable development.

• Innovation - sustained investment in R&D, technology platforms, and new therapeutic solutions.
• Integrity - compliance with regulations, ethical business conduct, and patient-first principles.
• Cooperation - strategic partnerships, industrial matching, and capital socialization to accelerate scale.
• Inclusiveness - creating value across stakeholders: patients, employees, partners, and society.
• Responsibility - corporate social responsibility in health access, safety, and environmental stewardship.

• Groupization: consolidate affiliate operations and portfolios to realize economies of scale and cross-functional synergies.
• Product serialization: broaden and standardize product lines to support brand strength and regulatory consistency.
• Capital socialization: leverage capital markets, M&A, and partnerships to fund expansion and technological upgrades.
• Internationalization: expand registration, distribution, and commercial presence across target regions to enhance global competitiveness.

Sunflower Pharmaceutical Group Co.,Ltd (002737.SZ) - Vision Statement

• Innovation: Continuous R&D investment to accelerate new therapeutic development and formulation optimization.
• Integrity: Transparent governance, compliance with regulatory standards, and strict ethical conduct across the value chain.
• Cooperation: Strategic partnerships with hospitals, research institutes, distributors, and global pharma players to enhance patient access.
• Inclusiveness: Product portfolios and pricing strategies designed to serve diverse patient populations, including underserved regions.
• Responsibility: Active measures to reduce environmental footprint, ensure workplace safety, and contribute to community health programs.
• Quality: Robust quality management systems across manufacturing, quality control, and post-market surveillance.

• Accelerated clinical and formulation programs: prioritizing biosimilars, high-value generics, and specialty injectables to lift gross margins and therapeutic impact.
• Quality system upgrades: GMP facility investments and digital manufacturing controls to reduce batch deviations and recall risk.
• Collaborative networks: M&A and licensing partnerships to acquire niche technologies and enter new geographic markets faster.
• Access and affordability programs: tiered pricing and distribution agreements to expand reach into lower-income provinces and export markets.
• ESG and responsibility actions: emissions and waste reduction targets; employee safety metrics and community healthcare initiatives.

• R&D intensity: raise R&D spend to 7-8% of revenue within 24-36 months to support new molecular entities and formulation upgrades.
• Revenue growth: target 10-12% CAGR over the next 3 years via portfolio optimization and international expansion.
• Margin improvement: aim to expand net profit margin by 1-2 percentage points through portfolio mix shift and manufacturing efficiencies.
• Market diversification: increase export share to 20% within 3 years through targeted registrations and partnerships.